<?xml version="1.0"?>

<document>
	<title>High dosage tobramycin treatment of children with cystic fibrosis.
   Bacteriological effect and clinical ototoxicity.</title>

	<author>Thomsen-J.</author>
	<author>Friis-B.</author>

	<source>Int-J-Pediatr-Otorhinolaryngol. 1979 Jul. 1(1). P 33-40.</source>

	<abstract>The bacteriological effect of chemotherapy against mucoid strains of
   Pseudominas aeruginosa in the lower respiratory tract of patients
   with cystic fibrosis is reported. A comparison of the effect of high
   doses of tobramycin (10 mg/kg/24 h) given alone or in combination
   with carbenicillin showed a significant difference in favour of the
   combination therapy. In 74.5% of the initially successful courses the
   patients were recolonized within one month. Fifty-three patients were
   examined by audiometric and vestibular tests. Only in one patient was
   it possible to register a transient, high tone hearing impairment at
   8000 Hz bilaterally, that might be attributed to the tobramycin
   treatment. It is concluded that high dose tobramycin treatment in
   children and adolescents with normal kidney function implies only a
   minimal clinical risk of adverse ototoxic effects, even after
   repeated courses of treatment. No nephrotoxic side-effects were found
   in this material.</abstract>

	<majorsubject>ANTIBIOTICS: ad</majorsubject>
	<majorsubject>CYSTIC-FIBROSIS: co</majorsubject>
	<majorsubject>PSEUDOMONAS-INFECTIONS: dt</majorsubject>
	<majorsubject>RESPIRATORY-TRACT-INFECTIONS: dt</majorsubject>
	<majorsubject>TOBRAMYCIN: ad</majorsubject>

	<minorsubject>CARBENICILLIN: ad</minorsubject>
	<minorsubject>CHILD</minorsubject>
	<minorsubject>DRUG-THERAPY-COMBINATION</minorsubject>
	<minorsubject>FEMALE</minorsubject>
	<minorsubject>HUMAN</minorsubject>
	<minorsubject>MALE</minorsubject>
	<minorsubject>PSEUDOMONAS-INFECTIONS: co, mi</minorsubject>
	<minorsubject>RESPIRATORY-TRACT-INFECTIONS: co, mi</minorsubject>
	<minorsubject>TOBRAMYCIN: ae</minorsubject>

	<reference>001   BRUMMET RE            ARCH OTOLARYNGOL               101   540 975</reference>
	<reference>002   BRUMMET RE            ARCH OTOLARYNGOL                96   505 972</reference>
	<reference>004   HOFF GE               SCAND J INFECT DIS               6   333 974</reference>
	<reference>005   LOGAN TB              ARCH OTOLARYNGOL                99   190 974</reference>
	<reference>006   MCCRAE WM             SCOTT MED J                     21    68 976</reference>
	<reference>007   NEU HC                J INFECT DIS SUPPL             134   206 976</reference>
	<reference>008   STUPP HF              ACTA OTOLARYNGOL STOCKH SUPPL  262     1 970</reference>
	<reference>009   WILSON P              BR MED J                         1   259 977</reference>

	<citation>1   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982</citation>
	<citation>2   SCHOFIELD DH          DRUG INTEL CLIN PHARM           18   153 984</citation>
	<citation>3   MILLER JJ             LANCET                           2   272 985</citation>
	<citation>4   CHRYSTYN H            J CLIN HOSP PHARM               10   219 985</citation>
	<citation>5   FRASER GL             DRUG INTEL CLIN PHARM           19   757 985</citation>

</document>
